Incidence of Severe COVID-19 Illness Following Vaccination and Booster With BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines.

ABSTRACT:

Importance

Evidence describing the incidence of severe COVID-19 illness following vaccination and booster with BNT162b2, mRNA-1273, and Ad26.COV2.S vaccines is needed, particularly for high-risk populations.

Objective

To describe the incidence of severe COVID-19 illness among a cohort that received vaccination plus a booster vaccine dose.

Design, setting, and participants

Retrospective cohort study of adults receiving care at Veterans Health Administration facilities across the US who received a vaccination series plus 1 booster against SARS-CoV-2, conducted from July 1, 2021, to May 30, 2022. Patients were eligible if they had received a primary care visit in the prior 2 years and had documented receipt of all US Food and Drug Administration-authorized doses of the i

SUBMITTER: Kelly JD 

PROVIDER: S-EPMC9513709 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature